1
Participants
Start Date
December 23, 2019
Primary Completion Date
December 31, 2022
Study Completion Date
December 31, 2022
Escitalopram
Participants are given escitalopram for 8 weeks. At week 8, those classified as responders will continue on escitalopram until the end of study.
Brexpiprazole
Participants who are classified as non-responders are given 8 weeks add-on brexpiprazole, in addition to escitalopram, for the remainder of the study.
University of Calgary, Calgary
University of British Columbia, Vancouver
McMaster University, Hamilton
Queen's University, Kingston
University Health Network, Toronto
Centre for Addiction and Mental Health, Toronto
Unity Health Toronto
OTHER
Baycrest
OTHER
Centre for Addiction and Mental Health
OTHER
McMaster University
OTHER
Queen's University
OTHER
University of Ottawa
OTHER
University of British Columbia
OTHER
University of Calgary
OTHER
McGill University
OTHER
Dalhousie University
OTHER
University of Michigan
OTHER
Simon Fraser University
OTHER
University Health Network, Toronto
OTHER